ABA	ABATACEPT
AE	Acute exacerbation
ANTI-MDA5	Anti–melanoma differentiation–associated protein 5
AZA	Azathioprine
BDMARDS	Biologic disease modifying anti-rheumatic drugs
CDMARDS	Conventional disease modifying anti-rheumatic drugs
COPD	Chronic obstructive pulmonary disease
CTD	Connective tissue diseases
CTD-ILD	Connective tissue diseases-realated interstitial lung disease
CYC	Cyclophosphamide
DLCO	Diffusing capacity of the lungs for carbon monoxide
DMARDS	Disease modifying anti-rheumatic drugs
FVC	Forced vital capacity
HRCT	High-resolution computer tomography
ILD	Interstitial lung disease
IPF	Idiopathic pulmonary fibrosis
JAK	Janus-kinase
LEF	Leflunomide
MDA5	Melanoma differentiation–associated protein 5
MDSC	Myeloid-derived suppressor cells
MMF	Mycophenolate mofetil
MTX	Methotrexate
NICE	National Institute for Health and Care Excellence
NS-CTLD	Non-scleroderma connective tissue-related lung disease
NSIP	Nonspecific interstitial pneumonia
OP	Organizing pneumonia
PFTS	Pulmonary function tests
RA	Rheumatoid arthritis
RA-ILD	Rheumatoid arthritis-related interstitial lung disease
RTX	Rituximab
SSC-ILD	Systemic sclerosis-related interstitial lung disease
TCZ	Tocilizumab
TNFI	Tumour necrosis factor alpha inhibitor
TSDMARDS	Targeted synthetic disease modifying anti-rheumatic drugs
UIP	Usual interstitial pneumonia